Perhaps no literary genre has made quite as big of a splash in recent years as the fantasy-romance segment, colloquially known as “romantasy”—a phenomenon that Organon is capitalizing on in its newest ad campaign. More: Organon taps into 'romantasy' craze
read more
Screening begins for study evaluating LTI-03 in idiopathic pulmonary fibrosi More: Rein Therapeutics initiates renew phase 2 trial for IPF treatment Source: News
read moreThanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of blockbuster Xarelto in the first quarter. More: As Bayer's restructuring
read moreAfter a decade of follow-up, Roche’s Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer. More: Roche spotlights Perjeta's staying power with 10-year breast cancer survival results Source: fierce
read moreBluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers Carlyle and SK Capital to extend their offer once again. More: Bluebird bio warns of potential bankruptcy as buyout faces another
read moreNovo Nordisk has unveiled data from the phase 3 REAL8 trial, which found that the company’s once-weekly human growth hormone analogue Sogroya was largely on par with its daily predecessor, Norditropin, in a trio of growth disorders in kids. More:
read more© 1994 - 2025 B.M. Pharmaceuticals